Comments on a consensus regarding diagnostic criteria for neuroleptic malignant syndrome.

نویسندگان

  • Branimir Margetić
  • Branka Aukst-Margetić
چکیده

To the Editor: A group of distinguished experts on neuroleptic malignant syndrome (NMS) has reached a consensus regarding diagnostic criteria for NMS using the Delphi technique under the coordination of Dr Ronald J. Gurrera.1 It is logical to assume that the use of the Delphi technique would result in a more acceptable set of criteria and probably lead to advantages for future research on NMS. However, the implementation of this consensus may lead to some important changes and presumed advantages in the understanding of the condition that were not mentioned by the authors. For example, according to DSM-IV-TR, NMS is associated with the use of neuroleptic medication. However, according to this consensus, NMS may be associated with the use of a dopamine antagonist or with dopamine agonist withdrawal. Indirectly, this indicates a consensus that the term neuroleptic malignant syndrome is a misnomer. Therefore, it seems that a different designation for the syndrome would be appropriate, and it would be interesting to see whether a consensus on that issue would be possible. Furthermore, although the consensus by this group is not related to the nature of the condition, it is worth noting that in dozens of publications NMS is described as an idiosyncratic reaction. However, idiosyncratic reactions are most likely caused by reactive metabolites of some drugs,2 not by drug withdrawals. Accordingly, the group’s inclusion of dopamine agonist withdrawal as a cause of NMS indicates a consensus that NMS is not an idiosyncratic reaction, at least in some cases. However, many aspects of NMS remain controversial.3 The question of fundamental clinical interest is when to start treatment of the condition. Clinicians must not be conservative, but should they treat the condition when no criteria are fulfilled, or even when the development of NMS is only under consideration? Aside from the question of which criteria to use, there is a gap between a need for criteria, which are necessary for improvement of research, and a need for a prompt clinical reaction. Ideally, the treatment of the condition when no criteria are fulfilled should prevent the development of the full-blown picture of NMS. Thus, it is unclear whether the criteria for diagnosis and the criteria for treatment should be the same.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Neuroleptic malignant syndrome.

Few conditions have attracted such widespread attention among both neurologists and psychiatrists in recent years as the neuroleptic malignant syndrome. First described in 1960 by French clinicians in a study of haloperidoll and subsequently named the "syndrome malin des neuro-leptiques",2 this nomenclature suffered in translation to the neuroleptic malignant syndrome; this term has endured, in...

متن کامل

Proposed research diagnostic criteria for neuroleptic malignant syndrome.

Many sets of diagnostic criteria have been proposed for neuroleptic malignant syndrome (NMS) but there is a lack of uniformity. No universally agreed criteria exist currently for research purposes, thus making comparisons across studies very difficult. Most of them have flaws and detect too many false-positives based on an over-inclusive definition. The estimates of incidence rates of NMS vary ...

متن کامل

Neuroleptic malignant syndrome.

Neuroleptic malignant syndrome is a rare but serious adverse effect of antipsychotic medication. The author describes three new cases and reviews 50 others published in the past 5 years. Demographic and clinical features, diagnosis, treatment, outcome, and pathophysiology are critically reviewed, and a new set of diagnostic criteria, incorporating physical signs and routine laboratory tests, is...

متن کامل

Elevated creatine kinase does not necessarily correspond temporally with onset of muscle rigidity in neuroleptic malignant syndrome: a report of two cases

Neuroleptic malignant syndrome is an uncommon but dangerous complication of antipsychotic drugs, characterized by clinical symptoms that include hyperthermia, severe muscle rigidity, autonomic dysfunction, and altered mental state. Serum creatine kinase (CK) elevation occurs in over 90% of cases. Many diagnostic criteria sets for neuroleptic malignant syndrome have been proposed, all of which i...

متن کامل

Olanzapine-Induced Neuroleptic Malignant Syndrome

Neuroleptic malignant syndrome (NMS) is a rare but life-threatening idiosyncratic side effect resulting from neuroleptic drugs. NMS mainly occurs in patients treated with high-potency typical antipsychotics, but rarely caused by atypical antipsychotics. Although NMS is less common with atypical antipsychotic, but it seems that its incidence is rising due to increased administration of such drug...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • The Journal of clinical psychiatry

دوره 73 2  شماره 

صفحات  -

تاریخ انتشار 2012